Literature DB >> 20128647

Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity.

Paul S Cheung1, Erwin C Si, Kamran Hosseini.   

Abstract

Growing data suggest that the antibiotic azithromycin mediates anti-inflammatory activity through the inhibition of the transcription factor NF-kappaB. The purpose of this study was to compare azithromycin's anti-inflammatory potency with that of hydrocortisone and dexamethasone as measured in an activated NF-kappaB assay. Dose-response curves and the corresponding inhibitory potencies (IC(50)) of azithromycin, hydrocortisone, and dexamethasone were evaluated in a fluorescence assay using A549 cells. All three compounds inhibited TNFalpha stimulated NF-kappaB activity in a dose-dependent manner. IC(50) values of azithromycin, hydrocortisone and dexamethasone were 56 microM, 2.6 nM, and 0.18 nM, respectively. Hydrocortisone was approximately 4 orders of magnitude more potent than azithromycin, while dexamethasone was approximately 14 times as potent as hydrocortisone. In relative terms the anti-inflammatory potency of azithromycin was about 4 orders of magnitude weaker than that of hydrocortisone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20128647     DOI: 10.3109/09273940903359725

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  12 in total

1.  Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells.

Authors:  De-Quan Li; Nan Zhou; Lili Zhang; Ping Ma; Stephen C Pflugfelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

Review 2.  Phosphorylation mechanisms in intensive care medicine.

Authors:  Erica L Martin; V Marco Ranieri
Journal:  Intensive Care Med       Date:  2010-09-04       Impact factor: 17.440

3.  Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-κB Signaling Pathways.

Authors:  Dalia Haydar; Theodore J Cory; Susan E Birket; Brian S Murphy; Keith R Pennypacker; Anthony P Sinai; David J Feola
Journal:  J Immunol       Date:  2019-07-01       Impact factor: 5.422

Review 4.  Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.

Authors:  Vincent J Venditto; David J Feola
Journal:  Adv Drug Deliv Rev       Date:  2022-03-30       Impact factor: 17.873

5.  The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms.

Authors:  Petra Zimmermann; Victoria C Ziesenitz; Nigel Curtis; Nicole Ritz
Journal:  Front Immunol       Date:  2018-03-13       Impact factor: 7.561

6.  SupplAzithromycin for Prevention of Graft-Versus-Host Disease: A Randomized Placebo-Controlled Trial.

Authors:  Maryam Barkhordar; Mehdi Mohammadi; Molouk Hadjibabaie; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-04-01

Review 7.  The signal pathways and treatment of cytokine storm in COVID-19.

Authors:  Lan Yang; Xueru Xie; Zikun Tu; Jinrong Fu; Damo Xu; Yufeng Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-07

8.  Azithromycin reduces inflammation in a rat model of acute conjunctivitis.

Authors:  Patricia Fernandez-Robredo; Sergio Recalde; Maite Moreno-Orduña; Laura García-García; Javier Zarranz-Ventura; Alfredo García-Layana
Journal:  Mol Vis       Date:  2013-01-28       Impact factor: 2.367

Review 9.  A New, Potent, and Placenta-Permeable Macrolide Antibiotic, Solithromycin, for the Prevention and Treatment of Bacterial Infections in Pregnancy.

Authors:  Jeffrey A Keelan; Matthew S Payne; Matthew W Kemp; Demelza J Ireland; John P Newnham
Journal:  Front Immunol       Date:  2016-04-01       Impact factor: 7.561

10.  Contribution of anti-inflammatory and anti-virulence effects of azithromycin in the treatment of experimental Staphylococcus aureus keratitis.

Authors:  Kana Ikemoto; Shinya Kobayashi; Yu Haranosono; Seiko Kozai; Tomoyuki Wada; Hideki Tokushige; Akio Kawamura
Journal:  BMC Ophthalmol       Date:  2020-03-06       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.